Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Omnicell
OMCL
Omnicell
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
27 May 25
Updated
24 Jul 25
2
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
US$43.83
30.4% undervalued
intrinsic discount
24 Jul
US$30.50
Loading
1Y
-26.2%
7D
3.0%
Author's Valuation
US$43.8
30.4% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
US$43.8
30.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-23m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.2b
Earnings US$10.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
3.21%
Medical Equipment revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.07%
Calculation
US$10.45m
Earnings '28
x
256.49x
PE Ratio '28
=
US$2.68b
Market Cap '28
US$2.68b
Market Cap '28
/
49.49m
No. shares '28
=
US$54.17
Share Price '28
US$54.17
Share Price '28
Discounted to 2025 @ 7.67% p.a.
=
US$43.40
Fair Value '25